Gastrointestinal Cancer

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

TACE plus atezolizumab and bevacizumab may represent effective option for untreated intermediate-to-high tumor burden unresectable HCC.

The addition of TTFields to chemotherapy improved quality of life and delayed time to pain deterioration in locally advanced pancreatic cancer.

Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Ronan J. Kelly, MD, discusses efficacy and safety data from the phase 3 CheckMate 577 study of adjuvant nivolumab in esophageal/GEJ cancer.

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.

Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.

Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.

Irpagratinib combined with atezolizumab was effective and safe in both treatment-naive and ICI-exposed advanced HCC with FGF19 overexpression.

Certepetide plus gemcitabine and nab-paclitaxel was safe and effective in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

Zanidatamab has become the first HER2-targeted agent to gain conditional approval for HER2-positive biliary tract cancer in the European Union.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

Elraglusib plus gemcitabine and nab-paclitaxel lead to an OS benefit vs chemotherapy alone in treatment-naive metastatic PDAC.

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and effectiveness.

Panelists discuss how standard-of-care treatment follows NCCN guidelines with sequential kinase inhibitor therapy (imatinib, sunitinib, regorafenib, ripretinib), emphasizing that maintaining some form of kinase inhibition is always preferable to no treatment even after progression.